Less Ads, More Data, More Tools Register for FREE

Pin to quick picksChesnara Regulatory News (CSN)

Share Price Information for Chesnara (CSN)

Share Price is delayed by 15 minutes
Get Live Data
317.50    0.50 (0.16%)
Bid:
315.50
Ask:
317.00
Spread: 1.50 (0.475%)
Market Cap: £732.37m
CSN Live PriceLast checked at - London Stock Exchange

Intraday Chesnara Share Chart

Directorate Change

12 May 2021 07:00

RNS Number : 2977Y
Chesnara PLC
12 May 2021
 

CHESNARA plc

("Chesnara" or "the Company")

 

12 May 2021

 

LEI Number: 213800VFRMBRTSZ3SJ06

 

 

CHANGE OF DIRECTORSHIP PLANNED FOR CHESNARA PLC

 

Chesnara today announces John Deane's intended retirement from the Company. He will be stepping down as Group Chief Executive Officer by the end of the year.

 

Under John Deane's six-year leadership, the Company has paid its shareholders £171m in dividends and seen the EcV of the group increase by £220m to £637m at 31 December 2020.

 

Luke Savage, Chairman, said: "John has made a significant contribution to Chesnara during his tenure, not least to the group's excellent financial track record. He will continue at the helm for the intervening period and ensure that there is a seamless handover to his successor. Both John and I will carry on delivering and progressing the group's strategic objectives and initiatives. So, for our customers, shareholders, staff and other stakeholders, it will feel like 'business as usual' given Chesnara's continued commitment to its existing strategy."

 

John Deane, Chief Executive said: "After six years at Chesnara and supporting the chairmanship change from Peter Mason to Luke, the timing is right for me to retire. I am not winding down just yet and will enjoy continuing to work with the team to achieve a smooth transition while making sure the group keeps on delivering value to all of our stakeholders."

 

The Company is also announcing that it has identified Steve Murray as intended successor to the role of Chief Executive. Steve has over twenty years' experience within the life assurance industry and a well-established track record in M&A, wider commercial leadership roles and experience of growing a business in "1825", Standard Life's financial advisory business. He will be appointed as an Executive Director and take up the role of Group Chief Executive Officer of Chesnara. Steve leaves his role as Chief Commercial Officer at Royal London to join Chesnara.

 

Steve Murray, Chief Executive Designate said: "I am delighted to be joining Chesnara later this year. I look forward to working closely with John and the wider team in my step into the Group Chief Executive role as we look to build on the company's successful and well-established strategy. I am excited by the opportunities we have ahead of us."

 

 

 

There are no matters to disclose in accordance with LR 9.6.13. The Company will make further announcements in due course and provide additional details of Steve Murray's appointment.

 

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

 

For further information, please contact:

 

 

 

Roddy Watt

Director, Capital Markets

FWD

Forward thinking communications

 

T - 020 7280 0651

E - roddy.watt@fwdconsulting.co.uk 

 

 

Notes to Editors

Chesnara is a life and pensions company listed on the London Stock Exchange. It administers over one million policies and operates as Countrywide Assured in the UK, as The Waard Group and Scildon in the Netherlands, and as Movestic in Sweden.

 

Following a three-pillar strategy, Chesnara's primary responsibility is the efficient administration of its customers' life and savings policies, ensuring good customer outcomes and providing a secure and compliant environment to protect policyholder interests. It also adds value by writing profitable new business in Sweden and the Netherlands and by undertaking value-adding acquisitions of either companies or portfolios.

 

Consistent delivery of the Company strategy has enabled Chesnara to increase its dividend for 16 years in succession.

 

Further details are available on the Company's website (www.chesnara.co.uk).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAABMMTMTABTMB
Date   Source Headline
1st Jun 20267:00 amRNSDirector/PDMR Shareholding and Total Voting Rights
29th May 20267:00 amRNSDirector/PDMR Shareholding
27th May 20267:00 amRNSDirector/PDMR Shareholding
19th May 20267:00 amRNSDirector/PDMR Shareholding
14th May 20267:00 amRNSDirector/PDMR Shareholding
12th May 20262:00 pmRNSResult of AGM
1st May 20267:00 amRNSTotal Voting Rights
28th Apr 20267:00 amRNSDirector/PDMR Shareholding
17th Apr 20267:00 amRNSAdmission to Trading
10th Apr 20267:00 amRNSHolding(s) in Company
9th Apr 20267:00 amRNSNotice of AGM
1st Apr 20267:00 amRNSTotal Voting Rights
31st Mar 20267:00 amRNSDirector/PDMR Shareholding
27th Mar 20263:40 pmRNSDirector/PDMR Shareholding
27th Mar 20267:00 amRNSDirector/PDMR Shareholding
26th Mar 20267:00 amRNSDirector/PDMR Shareholding
24th Mar 20267:00 amRNSFinal Results
3rd Mar 20267:00 amRNSTotal Voting Rights
2nd Mar 20267:00 amRNSHolding(s) in Company
27th Feb 20267:00 amRNSUpdated Financial Framework and Notice of Results
17th Feb 20267:00 amRNSAcquisition
2nd Feb 20267:00 amRNSCompletion of HSBC Life (UK) Limited Acquisition
30th Jan 20262:00 pmRNSTotal Voting Rights
31st Dec 20257:00 amRNSTotal Voting Rights
31st Dec 20257:00 amRNSTotal Voting Rights
12th Dec 20251:45 pmRNSRegulatory Approval
12th Dec 20257:00 amRNSChange of Registered Office
9th Dec 20257:00 amRNSHolding(s) in Company
2nd Dec 20257:00 amRNSHolding(s) in Company
7th Nov 20257:00 amRNSTotal Voting Rights
30th Oct 20257:00 amRNSHolding(s) in Company
28th Oct 20257:00 amRNSBlock listing Interim Review
27th Oct 202512:04 pmRNSDirector/PDMR Shareholding
6th Oct 20257:00 amRNSTotal Voting Rights
28th Aug 20257:00 amRNSHalf-year Report
14th Aug 20257:00 amRNSNotice of Interim Results
13th Aug 20256:00 pmRNSPrimary Health Properties
30th Jul 20257:00 amRNS£150 MILLION RESTRICTED TIER 1 BOND ISSUE
28th Jul 20257:00 amRNSDirector/PDMR Shareholding
23rd Jul 202510:52 amRNSResult of Rump Placing
23rd Jul 20258:15 amRNSDirector/PDMR Shareholding
23rd Jul 20257:00 amRNSAnnouncement re: Rights Issue
8th Jul 20257:00 amRNSAdmission of Nil Paid Rights
3rd Jul 202512:10 pmRNSPublication of a Prospectus
3rd Jul 20257:00 amRNSAcquisition & Rights Issue
1st Jul 20257:00 amRNSTotal Voting Rights
17th Jun 20257:00 amRNSDirector/PDMR Shareholding
10th Jun 20257:00 amRNSDirector/PDMR Shareholding
6th Jun 20257:00 amRNSDirectorate Change
23rd May 20257:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.